1. Home
  2. RFL vs ICCC Comparison

RFL vs ICCC Comparison

Compare RFL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.54

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$5.48

Market Cap

55.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFL
ICCC
Founded
2017
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.4M
55.5M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
RFL
ICCC
Price
$1.54
$5.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
122.1K
18.8K
Earning Date
11-19-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$917,000.00
$27,769,304.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$21.23
Revenue Growth
43.96
16.49
52 Week Low
$1.17
$4.28
52 Week High
$3.19
$7.60

Technical Indicators

Market Signals
Indicator
RFL
ICCC
Relative Strength Index (RSI) 76.97 53.46
Support Level $1.21 $4.72
Resistance Level $1.29 $5.36
Average True Range (ATR) 0.08 0.31
MACD 0.03 0.12
Stochastic Oscillator 95.00 77.73

Price Performance

Historical Comparison
RFL
ICCC

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: